Professor Im Joo Rhyu, director of the Korea University Graduate Program for Convergence & Translational Biomedicine and ...

Professor Im Joo Rhyu, director of the Korea University Graduate Program for Convergence & Translational Biomedicine and faculty member in the Department of Anatomy, recently led a study investigating ...

MELBOURNE, Australia (AP) — An Australian man credited with saving 2.4 million babies through his record-breaking blood plasma donations over six decades, has died, his family said Tuesday. He was 88.

Mean corpuscular hemoglobin (MCH) is a measurement of the average amount of hemoglobin within a red blood cell. MCH that's lower or higher than normal may indicate you have a condition such as ...

“Immunoglobulins recognise dangerous micro-organisms and help the immune cells to neutralise them. It’s a vital treatment for people with immune disorders. “We urge people in Cornwall to try blood ...

a doctor will take a blood sample and order a test that separating red blood cells from plasma. If a doctor has the necessary equipment, testing may take place in their office. Alternatively ...

Ballard Power Systems has secured a multi-year supply agreement from Egyptian bus and truck producer Manufacturing Commercial Vehicles (MCV) for fuel cell engines totalling 5MW. Under the supply ...

SYDNEY, Australia — James Harrison, a prolific Australian blood donor famed for having saved the lives of more than 2 million babies, has died at age 88. Harrison, whose plasma contained a "rare ...

To overcome this, herein blood cells were used as they are easy and routinely to isolate. Within this study we provide detailed protocols for determination of the autophagic flux in peripheral blood ...

Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year ago appears to have paid off as the drug reduced blood procedures among patients with a rare type of cancer in a ...

An experimental medicine from Protagonist Therapeutics stabilized red blood cells and improved symptoms in patients with a rare blood cancer — achieving the efficacy goals of a Phase 3 study.